Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EC905

- PMLiVE

Astellas selects new CFO for its EMEA operations

Japanesefirm also appoints newmanager for its US corporate affairs team

- PMLiVE

Astellas launches cancer challenge social media campaign

Teamsup with USA Rugby and the Australian Rugby Union for #pass4prostate

- PMLiVE

Astellas forms new US corporate affairs unit

Jeff Winton will lead the department, which adds two newemployees

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

- PMLiVE

Astellas signs up to immuno-oncology deal

Japanese firm the latest pharma company to buy into the next-gen cancer therapy area

- PMLiVE

Nurturing innovation in a tough environment

Much has been achieved in the UK in recent years, but the NHS still has a way to go

- PMLiVE

US approval for Astellas’ new antifungal drug Cresemba

Japanese firm co-markets the azole antifungal agent with Basilea

- PMLiVE

Advagraf shows survival increase for liver transplant patients

Astellas drug shows significant improvement in study published in the AJT

- PMLiVE

Astellas joins trial data sharing website

Joins Bayer, Boehringer, GSK, Lilly, Novartis, Roche and more

- PMLiVE

FDA panel backs new antifungal Cresemba

Basilea/Astellas drug tipped to become a $500m product

- PMLiVE

Eric Terhaerdt leaves AZ for Astellas

Joins as senior VP of global development operations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links